Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mierzalne ogniska nowotworu widoczne w badaniach obrazowych
- •Rak nerki oporny na standardowe leczenie lub powracający po leczeniu
- •Dobry stan ogólny pacjenta (możliwość codziennych czynności)
- •Dostępne próbki tkanki nowotworowej do badań
✗ Disqualifies
- •Wcześniejsze leczenie podobnymi eksperymentalnymi lekami
- •Poważne reakcje alergiczne na leki immunologiczne
- •Niedawne chemioterapie (w ciągu 5 okresów półtrwania leku)
- •Przerzuty do mózgu (chyba że są ustabilizowane po leczeniu)
- •Aktywne choroby autoimmunologiczne (z wyjątkami)
- •Poważne zakaźenie wymagające antybiotyków w ostatnich 14 dniach
- •Inny aktywnie leczonego raka w ostatnich 2 latach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (26)
Xencor Investigative Site
Phoenix, United States
Xencor Investigative Site
Duarte, United States
Xencor Investigative Site
Sacramento, United States
Xencor Investigative Site
New Haven, United States
Xencor Investigative Site
Jacksonville, United States
Xencor Investigative Site
Atlanta, United States
Xencor Investigative Site
Chicago, United States
Xencor Investigative Site
Chicago, United States
Xencor Investigative Site
Louisville, United States
Xencor Investigative Site
Rochester, United States
Xencor Investigative Site
New Brunswick, United States
Xencor Investigative Site
New York, United States
Xencor Investigative Site
New York, United States
Xencor Investigative Site
Charlotte, United States
Xencor Investigative Site
Durham, United States
Xencor Investigative Site
Cincinnati, United States
Xencor Investigative Site
Columbus, United States
Xencor Investigative Site
Oklahoma City, United States
Xencor Investigative Site
Nashville, United States
Xencor Investigative Site
Seattle, United States
Xencor Investigative Site
Leuven, Belgium
Xencor Investigative Site
Bourdeaux, France
Xencor Investigative Site
Villejuif, France
Xencor Investigative Site
Barcelona, Spain
Xencor Investigative Site
Madrid, Spain
Xencor Investigative Site
Cambridge, United Kingdom
Trial contact
819-01 Study Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.